Compare · BIIB vs SCLX
BIIB vs SCLX
Side-by-side comparison of Biogen Inc. (BIIB) and Scilex Holding Company (SCLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and SCLX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $29.53B, about 409.2x SCLX ($72.2M).
- Over the past year, BIIB is up 51.2% and SCLX is up 64.1% - SCLX leads by 12.9 points.
- BIIB has been more active in the news (20 items in the past 4 weeks vs 7 for SCLX).
- BIIB has more recent analyst coverage (25 ratings vs 6 for SCLX).
- Company
- Biogen Inc.
- Scilex Holding Company
- Price
- $200.00+0.04%
- $8.50-3.19%
- Market cap
- $29.53B
- $72.2M
- 1M return
- -2.21%
- +28.21%
- 1Y return
- +51.19%
- +64.09%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 20
- 7
- Recent ratings
- 25
- 6
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Latest BIIB
- Director Hawkins William A was granted 1,505 shares, increasing direct ownership by 17% to 10,365 units (SEC Form 4)
- Director Sherwin Stephen A was granted 1,505 shares, increasing direct ownership by 11% to 15,193 units (SEC Form 4)
- Director Rowinsky Eric K was granted 1,505 shares, increasing direct ownership by 6% to 25,844 units (SEC Form 4)
- Director Mantas Jesus B was granted 1,505 shares, increasing direct ownership by 15% to 11,263 units (SEC Form 4)
- Director Langer Susan was granted 1,505 shares, increasing direct ownership by 29% to 6,634 units (SEC Form 4)
- Director Patolawala Monish D was granted 1,505 shares, increasing direct ownership by 41% to 5,215 units (SEC Form 4)
- Director Pangalos Menelas N converted options into 2,370 shares and was granted 1,505 shares (SEC Form 4)
- Director Minor Lloyd was granted 1,505 shares, increasing direct ownership by 64% to 3,875 units (SEC Form 4)
- Director Freire Maria C was granted 2,005 shares, increasing direct ownership by 29% to 8,820 units (SEC Form 4)
- Biogen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest SCLX
- Scilex Holding Company ("Scilex") Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities
- SEC Form EFFECT filed by Scilex Holding Company
- Scilex Holding Company ("Scilex") Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities
- SEC Form S-3 filed by Scilex Holding Company
- SEC Form EFFECT filed by Scilex Holding Company
- Scilex Holding Company ("Scilex") Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026
- SEC Form 10-Q filed by Scilex Holding Company
- SEC Form NT 10-Q filed by Scilex Holding Company
- Scilex Holding Company filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Scilex Holding Company